Table 1.
Patient characteristics.
| Characteristics | Overall, n = 61 | Characteristics | Overall, n = 61 |
|---|---|---|---|
| Age (mean, range) | 62 (24–93) | ||
| Gender, n (%) | Type, n (%) | ||
| Female | 19 (31.1) | Bone tumor | 37 (60.7) |
| Male | 42 (68.9) | Soft tissue tumor | 24 (39.3) |
| KPS, n (%) | Histopathology, n (%) | ||
| 100 | 10 (16.4) | Chordoma | 28 (45.9) |
| 90 | 35 (57.4) | Chondrosarcoma | 7 (11.5) |
| 80 | 6 (9.8) | Liposarcoma | 7 (11.5) |
| 70 | 4 (6.6) | Pleomorphic sarcoma | 5 (8.2) |
| 60 | 6 (9.8) | Spindle cell sarcoma | 4 (6.6) |
| Stage (Bone tumor), n (%) | Fibromyxoid sarcoma | 3 (4.9) | |
| Stage 1A | 8 (13.1) | Sarcoma, NOS | 3 (4.9) |
| Stage 1B | 21 (34.5) | Fibrosarcoma | 2 (3.3) |
| Stage 2A | 3 (4.9) | MPNST | 1 (1.6) |
| Stage 2B | 5 (8.2) | Rhabdomyosarcoma | 1 (1.6) |
| Stage (Soft tissue tumor), n (%) | Site, n (%) | ||
| Stage 1A | 3 (4.9) | Pelvis | 43 (70.5) |
| Stage 1B | 1 (1.6) | Limb | 10 (16.4) |
| Stage 2 | 3 (4.9) | Spine/paraspine | 5 (8.2) |
| Stage 3A | 12 (19.7) | Chest | 2 (3.3) |
| Stage 3B | 5 (8.2) | Retroperitoneum | 1 (1.6) |
| T classification (Bone tumor), n (%) | CIRT planning, n (%) | ||
| T1 | 11 (18.0) | Total dose (Gy) | 67.2 (64–70.4) |
| T2 | 26 (42.6) | GTV (cc) | 171.80 (78.90–928) |
| T classification (Soft tissue tumor), n (%) | Tumor grading, n (%) | ||
| T1 | 7 (11.5) | G1 | 28 |
| T2 | 13 (21.3) | G2 | 12 |
| T3 | 4 (6.6) | G3 | 15 |
| GX | 6 | ||
Abbreviations: Sarcoma, NOS = sarcoma not otherwise specified; MPNST = malignant peripheral sheath tumor; GTV = gross tumor volume.